← Back
Data updated: Mar 10, 2026
POINTVIEW HLDINGS
Pharmaceuticals
POINTVIEW HLDINGS is a generic drug manufacturer with 4 FDA-approved products.
2015
Since
4
Drugs
-
Trials
58
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
PREDNISONE 2025-10-01
MEMANTINE HYDROCHLORIDE 2025-08-28
MEMANTINE HYDROCHLORIDE 2025-04-25
Labeling
MEMANTINE HYDROCHLORIDE 2025-04-18
Manufacturing (CMC)
METHOCARBAMOL 2025-04-08
Labeling
CARISOPRODOL 2024-11-14
Labeling
PREDNISONE 2024-06-07
Labeling
PREDNISONE 2024-06-07
Labeling
PREDNISONE 2024-06-07
Labeling
PREDNISONE 2024-06-07
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
No indication data
Pipeline Strength Pro
Loading...
Active (0)
Discontinued (4)
Company Info
- First Approval
- 2015-09-04
- Latest
- 2024-06-07
- Applications
- 4